-

12:26:12 AM

LHDX Stock News

LHDX - Lucira Health Inc

05/12/22 4:01 PM

Nasdaq : LHDX

Lucira Health Announces First Quarter 2022 Results and Business Update

Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial

RHEA-AI

neutral

05/12/22 7:00 AM

Nasdaq : LHDX

covid-19

Lucira Files for Authorization of First-of-its-Kind COVID-19 & Flu At-Home Molecular Test

Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX),

RHEA-AI

neutral

05/09/22 8:00 AM

Nasdaq : LHDX

covid-19

Lucira Receives CE Mark for both COVID-19 & Flu and COVID-19 Molecular Tests

Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests, announced that both its COVID-19 & Flu and COVID-19

RHEA-AI

neutral

05/04/22 7:00 AM

Nasdaq : LHDX

conferences

Lucira Health to Participate in Bank of America 2022 Healthcare Conference

Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate in

RHEA-AI

neutral

04/28/22 7:00 AM

Nasdaq : LHDX

earnings

Lucira Health to Announce First Quarter 2022 Financial Results

Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report first

RHEA-AI

neutral

04/21/22 7:00 AM

Nasdaq : LHDX

partnership

LUCIRA HEALTH AND USA BOXING ANNOUNCE EXCLUSIVE PARTNERSHIP FOR THE 2022 SEASON

Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology

RHEA-AI

very positive

04/11/22 6:21 PM

Nasdaq : LHDX

Lucira Health Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that on April 6, 2022, the Board of Directors of

RHEA-AI

very positive

03/31/22 9:00 AM

Nasdaq : LHDX

covid-19

Lucira Donates Rapid Molecular At-Home COVID-19 Test Kits to Protect the Safety of Tonga Red Cross Society Workers

Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization

RHEA-AI

neutral

03/24/22 7:00 AM

Nasdaq : LHDX

covid-19

Lucira Health's PCR-Quality At-Home COVID-19 Test Now Available Direct to Consumers in Canada

Lucira Health, Inc.

RHEA-AI

neutral

03/10/22 4:01 PM

Nasdaq : LHDX

Lucira Health Announces Fourth Quarter and Full Year 2021 Results and Reaffirms 2022 Financial Outlook

Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported

RHEA-AI

neutral

LHDX Data

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.lucirahealth.com
Security nameLucira Health Inc
Issue typecs
SectorManufacturing
Sic code2835
Employees57

About Lucira Health Inc

Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular test results anywhere and at any time. The LUCIRA COVID19 All-In-One Test Kit is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection.